GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck KGaA (MIL:1MRK) » Definitions » Research & Development

Merck KGaA (MIL:1MRK) Research & Development : €2,279 Mil (TTM As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Merck KGaA Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Merck KGaA's Research & Development for the three months ended in Dec. 2024 was €527 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €2,279 Mil.

Merck KGaA Research & Development Historical Data

The historical data trend for Merck KGaA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck KGaA Research & Development Chart

Merck KGaA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,288.00 2,426.00 2,521.00 2,445.00 2,279.00

Merck KGaA Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 666.00 581.00 647.00 524.00 527.00

Merck KGaA Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,279 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck KGaA  (MIL:1MRK) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Merck KGaA Research & Development Related Terms

Thank you for viewing the detailed overview of Merck KGaA's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Merck KGaA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck KGaA (MIL:1MRK) » Definitions » Research & Development
Comparable Companies
XTER:EVT XTER:B8FK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA SHSE:688506 BOM:500087 TSE:4507 SZSE:000538 UTHR NSE:TORNTPHARM BOM:543904 BOM:500124 BOM:500257
Traded in Other Exchanges
MKKGY:USA MKGAF:USA MRKd:UK 0O14:UK MRKC:Germany MRK:Germany MRKC:Germany MRK:Germany MRK:Germany MRK:Germany MRK:Bulgaria MRCK:Austria
Address
Frankfurter Strasse 250, Darmstadt, HE, DEU, 64293
Website
https://www.emdgroup.com
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.

Merck KGaA Headlines

No Headlines